Company news

BioPorto A/S news in 2025

BioPorto A/S's news releases, calls and decks from 2025, newest first.

View company

Changes to the Executive Management

December 11, 2025

Managers’ transactions

November 24, 2025

BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes

November 24, 2025

BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth

November 19, 2025

Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S

November 13, 2025

BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement

November 13, 2025

Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs

November 4, 2025

Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025

November 4, 2025

Progress Update on BioPorto’s Adult Clinical Study

November 4, 2025

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented

September 26, 2025

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker

September 11, 2025

ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.

August 28, 2025

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.

August 15, 2025

BioPorto A/S to host an investor webcast on the results for the first half of 2025

July 29, 2025

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

July 28, 2025

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US

June 27, 2025

BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy

June 10, 2025

Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.

May 8, 2025

BioPorto A/S to host first quarter 2025 earnings webcast for investors

April 28, 2025

BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million

April 25, 2025

BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes

April 25, 2025

Decks in 2025